CRPC w/ Bone Metastases VL

Bone Health in Prostate Cancer - A Conversation with Neal Shore and Oliver Sartor

Details
Neal Shore and Oliver Sartor have a conversation on bone-targeted agent therapies in prostate cancer, specifically focusing on the ALSYMPCA phase three trial; the design, findings, the addition of radium-223 and what this trial has led to today. They review a few other current ongoing trials including the PEACE III single arm trial and other current approaches in understanding combination therapie...

A Nuclear Radiologist’s Perspective on Bone Targeted Therapies- Phillip Koo

Details
Phillip Koo shares with Charles Ryan his perspective on bone health from the view of the nuclear radiologist discussing proper imaging techniques leading to an accurate categorization of types of fractures; pathologic, either tumor-driven or insufficiency fractures vs post-traumatic. Closing comments lead to the clinical responsibilities to incorporate from the ERA 223 data in hope to enhance pati...

Decision Making When Treating Prostate Cancer - Silke Gillessen

Details
Silke Gillessen and Alicia Morgans discuss the need to be proactive with bone health in this patient population. In addition, Silke shares topics that will be discussed at the 2019 Advanced Prostate Cancer Consensus Meeting (APCCC). Biographies: Silke Gillessen, MD, Professor Medical Oncology, University of Berne, Switzerland. Co-founder of the Advanced Prostate Cancer Consensus Conference (APCCC)...

ERA 223: Presentation Summary from ESMO 2018 - Fred Saad

Details
(Length of Presentation: 8 min) Fred Saad presents: Abiraterone Acetate and Prednisone in Combination with Radium-223 or Placebo in Patients with Castration-Resistant Prostate Cancer in Bone Metastases: The Results of the Phase Three Trial. Biography: Fred Saad, MD FRCS, Full Professor and Chief of Urologic Oncology, Medical Director of Interdisciplinary Urologic Oncology Group, and Department of...

The Role of Bone Health Agents in Patients with Prostate Cancer - Tia Higano

Details
(Length of interview: 11 minutes) Tia Higano and Alicia Morgans share their perspective on the data analysis from the ERA-223 phase III study and highlight the value of incorporating bone health management, weight-bearing and resistance exercise when treating patients with prostate cancer. Biographies: Celestia (Tia) S. Higano, MD, Director, Prostate Cancer Clinical Research Group, Seattle Cancer...

A Renewed Analysis of ERA 223 - Fred Saad

Details
Charles Ryan and Fred Saad discuss the recent analysis of data points from ERA 223. (Length of Interview: 4 min) Biographies: Fred Saad, MD FRCS, Full Professor and Chief of Urologic Oncology, Medical Director of Interdisciplinary Urologic Oncology Group, Department of Surgery/Faculty of Medicine; Institut du cancer de Montréal/CRCHUM Charles J. Ryan, MD Referenced in this discussion: ERA 223 - A...

Prostate Cancer Osteomimicry in Circulating Tumor Cells in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) - Andrew Armstrong

Details
Andrew Armstrong and Alicia Morgans, discuss the PROPHECY trial, a prospective trial of circulating tumor cells, evaluating two current assays: the EPIC AR-V7 Nuclear Protein CTC and the Hopkins AR-V7 Adnatest. The conversation evolves to a discussion of the data from Armstrong's recent work shared at the 2018 ASCO GU meeting: measuring osteomimicry in three levels: RNA, DNA, and protein, potentia...

Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg

Details
Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion with Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2 nd line therapy. A relevant discussion follows on a Phase 2 trial investigating 3 different dosing regimens of radiu...

The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor

Details
Charles Ryan, MD, and Oliver Sartor, MD discuss bone health in the treatment of prostate cancer and then transition to discuss the novel theranostic opportunities that are in development for the treatment of prostate cancer including Lutetium-177 PSMA and Actinium PSMA-225. Lastly, they have a concise conversation about DNA mutations in prostate cancer and the implications of germ-line and somatic...

Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo

Details
(Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...